Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy

American Journal of Gastroenterology

Volumn 99, Issue 9, 2004, Pages 1738-1743

  Soffredini, Roberta ^b   Rumi, Maria Grazia ^b   Parravicini, Maria Luisa ^b   Ronchi, Guido ^b   Del Ninno, Ersilio ^b   Russo, Antonio ^b   Colombo, Massimo ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DNA DETERMINATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIREMIA; VIROLOGY;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL CORE PROTEINS;

EID: 4544374760     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.30396.x     Document Type: Article

References (25)

1. Aoyagi K, Ohue C, Iida K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999;37:1802-8.
2. Tanaka E, Ohue C, Aoyagi K, et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV-RNA. Hepatology 2000;32:388-93.
3. Zanetti A, Romanò L, Brunetto M, et al. Total HCV core Antigen assay: A new marker of hepatitis C viremia for monitoring the progress of therapy. J Med Virol 2003;70:27-30.
4. Bouvier-Alias M, Patel K, Dahari H, et al. Clinical utility of total HCV core antigen quantification: A new indirect marker of HCV replication. Hepatology 2002;36:211-18.
5. Maynard M, Pradat P, Berthillon P, et al. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy. J Viral Hepatitis 2003;10:318-23.
6. Veillon P, Payan C, Picchio G, et al. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and Amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol 2003;41:3212-20.
7. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002;36:S3-20.
8. EASL International Consensus Conference on Hepatitis C: Consensus statement. J Hepatol 1999;30:956-61.
9. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: Results of a U.S. multicenter randomized controlled study. N Engl J Med 1998;339:1485-92.
10. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
12. Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
13. Poynard T, McHutchison J, Goodman Z, et al. Is an "A la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000;31:211-18.
14. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-9.
15. Pawlotsky JM. Measuring hepatitis C viremia in clinical samples: Can we trust the assays? Hepatology 1997;26:1-4.
16. Gordon SC, Dailey PJ, Silverman AL, et al. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998;28:1702-6.
17. Pontisso P, Bellati G, Brunetto M, et al. Hepatitis C virus RNA profiles in chronically infected individuals: Do they relate to disease activity? Hepatology 1999;29:585-9.
18. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. NIH Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002;36:S65-73.
19. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
20. Davis GL. Monitoring of viral levels during therapy of hepatitis C. NIH Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002;36:S145-51.
21. Rumi MG, Del Ninno E, Parravicini ML, et al. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996;24:1366-70.
22. Saldanha J, Lelie N, Heath A. WHO Collaborative Study Group. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV-RNA. Vox Sang 1999;76:149-58.
23. Jorgensen PA, Neuwald PD. Standardized hepatitis C virus RNA panels for nucleic acid testing assays. J Clin Virol 2001;20:35-40.
24. Pontisso P, Carabaich A, Bernardinello E, et al. Correlation of HCV-RNA to total HCV core Antigen in chronic hepatitis C patients [abstract]. Hepatology 2002;36(suppl):1531A.
25. Maillard P, Krawczynski K, Nitkiewicz J, et al. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virology 2001;75:8240-50.